Department of Clinical Laboratory, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121001, China.
Department of Emergency Surgery, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121001, China.
Biomed Pharmacother. 2024 Aug;177:116985. doi: 10.1016/j.biopha.2024.116985. Epub 2024 Jun 19.
Chronic stress-mediated sustained release of neurotransmitters, which ultimately leads to the activation of β-adrenergic receptor (β-AR) signaling, is one of the most important reasons for triple-negative breast cancer (TBNC) progression. Quercetin (Que) has been proven to have the advantage of ameliorating stress psychological disorder. Our present study aimed to investigate the effect of Que on tumor growth and metastasis in TNBC xenograft mice undergoing stress, and to explore its underlying mechanisms. We first evaluated the effect of Que on the progression of TNBC in nude mice in vivo. The results showed that, Que could inhibit chronic stress-induced TNBC growth and occurrence of lung metastasis. We subsequently employed epinephrine (E) as a representative of stress hormone to investigate its possible mechanism in vitro. The results showed that, Que could inhibit E-mediated proliferation and migration of TNBC cells by blocking β-AR/ERK1/2 pathway. In conclusion, our data demonstrated that Que could inhibit chronic stress-induced ERK1/2 activity in TNBC cells, and thereby weakening the potential for TNBC growth and metastasis.
慢性应激介导的神经递质持续释放,最终导致β-肾上腺素能受体(β-AR)信号的激活,是三阴性乳腺癌(TNBC)进展的最重要原因之一。槲皮素(Que)已被证明具有改善应激性心理障碍的优势。本研究旨在探讨 Que 对经历应激的 TNBC 异种移植小鼠肿瘤生长和转移的影响,并探讨其潜在机制。我们首先评估了 Que 对体内裸鼠 TNBC 进展的影响。结果表明,Que 可抑制慢性应激诱导的 TNBC 生长和肺转移的发生。随后,我们采用肾上腺素(E)作为应激激素的代表,在体外研究其可能的机制。结果表明,Que 通过阻断β-AR/ERK1/2 通路抑制 E 介导的 TNBC 细胞增殖和迁移。总之,我们的数据表明,Que 可抑制慢性应激诱导的 TNBC 细胞中 ERK1/2 的活性,从而减弱 TNBC 生长和转移的潜力。
J Exp Clin Cancer Res. 2017-6-5
Acta Biochim Biophys Sin (Shanghai). 2024-5-25
Int J Mol Sci. 2024-6-1
Int J Nanomedicine. 2025-7-19
Mol Cancer. 2025-7-17
Signal Transduct Target Ther. 2025-4-18
Front Pharmacol. 2024-8-27